Cardiff Oncology, Inc. Financial Ratios
CRDF|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
-101.0%
Profit Margin
-7732.0%
Net Income / Revenue
Asset Turnover
0.01
Revenue / Total Assets
Equity Multiplier
1.36
Total Assets / Equity
Composite: -101.0% (reported: -101.0%)
Profitability
Liquidity
Current Ratio
3.67
Quick Ratio
3.67
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.01
Inventory Turnover
-
Days Sales Outstanding
112 days
As of FY2025 · SEC 10-K · Updated Jun 24, 2026
Earnings Quality
Accrual Ratio
-10.0%
+0.9pp YoY
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.